Cargando…

Seroprevalence of SARS-CoV-2 Antibodies Among Blood Donors in Malaysia During the Pre-Vaccination Period

PURPOSE: We aimed to investigate the prevalence of antibodies against SARS-CoV-2 virus among blood donors in Klang Valley; a cohort that represent healthy individuals in a city which recorded a high number of COVID-19 infections in the country. METHODS & MATERIALS: A total of 806 blood donors at...

Descripción completa

Detalles Bibliográficos
Autores principales: Shukri, A.M.A., Adnan, A., Mui, W. Seok, Mohamad, M., Kamal, F., Khalid, Z., Nawi, S.F.A. Mohd, Amin, N. Abu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884739/
http://dx.doi.org/10.1016/j.ijid.2021.12.080
_version_ 1784660226933260288
author Shukri, A.M.A.
Adnan, A.
Mui, W. Seok
Mohamad, M.
Kamal, F.
Khalid, Z.
Nawi, S.F.A. Mohd
Amin, N. Abu
author_facet Shukri, A.M.A.
Adnan, A.
Mui, W. Seok
Mohamad, M.
Kamal, F.
Khalid, Z.
Nawi, S.F.A. Mohd
Amin, N. Abu
author_sort Shukri, A.M.A.
collection PubMed
description PURPOSE: We aimed to investigate the prevalence of antibodies against SARS-CoV-2 virus among blood donors in Klang Valley; a cohort that represent healthy individuals in a city which recorded a high number of COVID-19 infections in the country. METHODS & MATERIALS: A total of 806 blood donors at the National Blood Centre were recruited between February to March 2021 during the third wave of the pandemic in Malaysia, a period just prior to the national COVID-19 vaccination programme began. 5 ml of blood were collected from each donor and the serum was subjected to qualitative determination of antibodies against SARS-CoV-2 virus using two tests. The first test detected total antibodies against SARS CoV-2 nucleocapsid (N) [Elecsys® Anti-SARS-CoV-2 Electrochemiluminescence immunoassay (ECLIA), Roche Diagnostics] while the second test detected the total antibodies against SARS-CoV-2 receptor binding domain (RBD) [WANTAI SARS-CoV-2 Antibody (Enzyme linked immunoassay (ELISA), China]. The tests were performed according to the manufacturer guidelines. The sera which produced positive results from both screening tests were then subjected to quantitative determination of antibodies against SARS-CoV-2 RBD [Elecsys® Anti-SARS-CoV-2 S (ECLIA), Roche Diagnostics] RESULTS: Out of 806 sera collected from the blood donors, qualitative screening of antibodies against SARS-CoV-2 virus showed 37 samples (4.59%) were positive for total antibodies against RBD, while 25 (3.10%) were positive against N proteins. 28 samples (3.47%) were tested positive by the quantitative determination of the antibodies. CONCLUSION: Our study revealed similar seroprevalence rate found in an identical study conducted in Los Angeles whereby 4.06% out of 865 collected sera were positive. While the blood donor population may not represent the Malaysian population in general, the finding of the seroprevalence in this group could indicate the rate of people infected with this virus is far more than reported and could aid public health decision making.
format Online
Article
Text
id pubmed-8884739
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-88847392022-03-01 Seroprevalence of SARS-CoV-2 Antibodies Among Blood Donors in Malaysia During the Pre-Vaccination Period Shukri, A.M.A. Adnan, A. Mui, W. Seok Mohamad, M. Kamal, F. Khalid, Z. Nawi, S.F.A. Mohd Amin, N. Abu Int J Infect Dis Ps04.26 (456) PURPOSE: We aimed to investigate the prevalence of antibodies against SARS-CoV-2 virus among blood donors in Klang Valley; a cohort that represent healthy individuals in a city which recorded a high number of COVID-19 infections in the country. METHODS & MATERIALS: A total of 806 blood donors at the National Blood Centre were recruited between February to March 2021 during the third wave of the pandemic in Malaysia, a period just prior to the national COVID-19 vaccination programme began. 5 ml of blood were collected from each donor and the serum was subjected to qualitative determination of antibodies against SARS-CoV-2 virus using two tests. The first test detected total antibodies against SARS CoV-2 nucleocapsid (N) [Elecsys® Anti-SARS-CoV-2 Electrochemiluminescence immunoassay (ECLIA), Roche Diagnostics] while the second test detected the total antibodies against SARS-CoV-2 receptor binding domain (RBD) [WANTAI SARS-CoV-2 Antibody (Enzyme linked immunoassay (ELISA), China]. The tests were performed according to the manufacturer guidelines. The sera which produced positive results from both screening tests were then subjected to quantitative determination of antibodies against SARS-CoV-2 RBD [Elecsys® Anti-SARS-CoV-2 S (ECLIA), Roche Diagnostics] RESULTS: Out of 806 sera collected from the blood donors, qualitative screening of antibodies against SARS-CoV-2 virus showed 37 samples (4.59%) were positive for total antibodies against RBD, while 25 (3.10%) were positive against N proteins. 28 samples (3.47%) were tested positive by the quantitative determination of the antibodies. CONCLUSION: Our study revealed similar seroprevalence rate found in an identical study conducted in Los Angeles whereby 4.06% out of 865 collected sera were positive. While the blood donor population may not represent the Malaysian population in general, the finding of the seroprevalence in this group could indicate the rate of people infected with this virus is far more than reported and could aid public health decision making. Published by Elsevier Ltd. 2022-03 2022-02-28 /pmc/articles/PMC8884739/ http://dx.doi.org/10.1016/j.ijid.2021.12.080 Text en Copyright © 2021 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Ps04.26 (456)
Shukri, A.M.A.
Adnan, A.
Mui, W. Seok
Mohamad, M.
Kamal, F.
Khalid, Z.
Nawi, S.F.A. Mohd
Amin, N. Abu
Seroprevalence of SARS-CoV-2 Antibodies Among Blood Donors in Malaysia During the Pre-Vaccination Period
title Seroprevalence of SARS-CoV-2 Antibodies Among Blood Donors in Malaysia During the Pre-Vaccination Period
title_full Seroprevalence of SARS-CoV-2 Antibodies Among Blood Donors in Malaysia During the Pre-Vaccination Period
title_fullStr Seroprevalence of SARS-CoV-2 Antibodies Among Blood Donors in Malaysia During the Pre-Vaccination Period
title_full_unstemmed Seroprevalence of SARS-CoV-2 Antibodies Among Blood Donors in Malaysia During the Pre-Vaccination Period
title_short Seroprevalence of SARS-CoV-2 Antibodies Among Blood Donors in Malaysia During the Pre-Vaccination Period
title_sort seroprevalence of sars-cov-2 antibodies among blood donors in malaysia during the pre-vaccination period
topic Ps04.26 (456)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884739/
http://dx.doi.org/10.1016/j.ijid.2021.12.080
work_keys_str_mv AT shukriama seroprevalenceofsarscov2antibodiesamongblooddonorsinmalaysiaduringtheprevaccinationperiod
AT adnana seroprevalenceofsarscov2antibodiesamongblooddonorsinmalaysiaduringtheprevaccinationperiod
AT muiwseok seroprevalenceofsarscov2antibodiesamongblooddonorsinmalaysiaduringtheprevaccinationperiod
AT mohamadm seroprevalenceofsarscov2antibodiesamongblooddonorsinmalaysiaduringtheprevaccinationperiod
AT kamalf seroprevalenceofsarscov2antibodiesamongblooddonorsinmalaysiaduringtheprevaccinationperiod
AT khalidz seroprevalenceofsarscov2antibodiesamongblooddonorsinmalaysiaduringtheprevaccinationperiod
AT nawisfamohd seroprevalenceofsarscov2antibodiesamongblooddonorsinmalaysiaduringtheprevaccinationperiod
AT aminnabu seroprevalenceofsarscov2antibodiesamongblooddonorsinmalaysiaduringtheprevaccinationperiod